Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Parameswaran Nair, Katherine Radford, Satoshi Nunomura, Manali Mukherjee, Kenji Izuhara
No abstract text is available yet for this article.
April 23, 2024: Allergy
#2
JOURNAL ARTICLE
Marek Niedoszytko, Aleksandra Gorska, Knut Brockow, Patrizia Bonadonna, Magdalena Lange, Hanneke Kluin-Nelemans, Hanneke Oude-Elberink, Vito Sabato, Khalid Shoumariyeh, Dagmar von Bubnoff, Sabine Müller, Anja Illerhaus, Michael Doubek, Irena Angelova-Fischer, Olivier Hermine, Michel Arock, Chiara Elena, Luca Malcovati, Akif Selim Yavuz, Tanja Daniela Schug, Anna Belloni Fortina, Várkonyi Judit, Jason Gotlib, Jens Panse, Vladan Vucinic, Andreas Reiter, Juliana Schwaab, Massimo Triggiani, Mattias Mattsson, Christine Breynaert, Jan Romantowski, Roberta Zanotti, Elisa Olivieri, Alexander Zink, Annick van de Ven, Alex Stefan, Stephane Barete, Francesca Caroppo, Cecelia Perkins, Vanessa Kennedy, Deborah Christen, Mohamad Jawhar, Johannes Luebke, Roberta Parente, Kerstin Levedahl, Emir Hadzijusufovic, Karin Hartmann, Boguslaw Nedoszytko, Wolfgang R Sperr, Peter Valent
BACKGROUND: Hypersensitivity reactions (HR) are common in mastocytosis. However, little is known about triggers and risk factors. The registry of the European Competence Network on Mastocytosis (ECNM) enables reliable studies in a larger cohort of mastocytosis patients. We assessed prevalence, triggers and risk factors of HR in adults with mastocytosis in the ECNM registry. METHODS: Data were collected in 27 ECNM centers. We analyzed potential triggers (Hymenoptera venoms, food, drug, inhalant and others) and risk factors at diagnosis and during follow-up...
April 23, 2024: Allergy
#3
LETTER
D Ünal, D Eyice-Karabacak, A Kutlu, S Demir, O C Tüzer, F A Arslan, S R Işık, A Gelincik
No abstract text is available yet for this article.
April 19, 2024: Allergy
#4
JOURNAL ARTICLE
Franziska Rademacher, Annika Scheel, Regine Gläser, Lena Schröder, Nina Heinemann, Joachim Bartels, Sascha Gerdes, Dora Stölzl, Elke Rodriguez, Katinka Döhner, Stephan Weidinger, Thomas Werfel, Jürgen Harder
BACKGROUND: The antimicrobial ribonuclease RNase 7 is abundantly expressed in the epidermis of lesional skin of atopic dermatitis (AD). Host RNase inhibitor (RI) binds to RNase 7 and blocks its ribonuclease activity. This study aimed to evaluate the impact of RNase 7-RI interactions on AD. METHODS: Cultured human primary keratinocytes, with siRNA-mediated downregulation of RNase 7 and RI, were stimulated with the synthetic RNA polyinosinic-polycytidylic acid (poly I:C)...
April 19, 2024: Allergy
#5
JOURNAL ARTICLE
Katie Ridge, Barry Moran, P Abigail Alvarado-Vazquez, Jenny Hallgren, Mark A Little, Alan D Irvine, Cliona O'Farrelly, Jean Dunne, Conor M Finlay, Niall Conlon
BACKGROUND: Chronic spontaneous urticaria (CSU) is a common, debilitating skin disorder characterized by recurring episodes of raised, itchy and sometimes painful wheals lasting longer than 6 weeks. CSU is mediated by mast cells which are absent from peripheral blood. However, lineage- CD34hi CD117int/hi FcεRI+ cells in blood have previously been shown to represent a mast cell precursor. METHODS: We enumerated FcεRI- , FcεRI+ and FcεRIhi lineage- CD34+ CD117+ cells using flow cytometry in blood of patients with CSU (n = 55), including 12 patients receiving omalizumab and 43 not receiving omalizumab (n = 43)...
April 17, 2024: Allergy
#6
LETTER
J Achour, M Reche, T Valbuena, C Chapuis, B Guillon, O Galet, K Adel-Patient, H Bernard, S Hazebrouck
No abstract text is available yet for this article.
April 15, 2024: Allergy
#7
JOURNAL ARTICLE
Simon Valentin, Veronique Regnault, Jean-Louis Gueant, Bruno Ribeiro Baptista, Thery Abel, Patrick Lacolley, Frederic Schlemmer, Ari Chaouat, François Chabot, Rosa-Maria Gueant-Rodriguez
No abstract text is available yet for this article.
April 12, 2024: Allergy
#8
LETTER
Lik Hang Lam, Weimin Li, Wai Chung Wu, Kai Cheung Chow, Wai Yin Dennis Au, Guolin Xu, Ge Wang, Xuchen Qian, Ka Man Ng, Shaik Abdullah Nawabjan, Muthu Iswarya Gandhi Sethuraman, Wai Yan Choi, Billy Kwok Chong Chow, Shui On Leung, Chin Wai Hui
No abstract text is available yet for this article.
April 9, 2024: Allergy
#9
REVIEW
Varsha Dwivedi, Sonja Kopanja, Klara Schmidthaler, Justyna Sieber, Christina Bannert, Zsolt Szépfalusi
The efficacy and safety of preventive allergen immunotherapy (pAIT) in children are currently under investigation. Here, we provide an overview of pAIT with respiratory allergens concerning the prevention of new sensitizations, allergic disease onset and progression as well as further immunomodulatory effects. Three databases were searched for clinical pAIT studies in children. Selected publications were reviewed for preventive outcomes according to prevention level (primary, secondary, and tertiary), allergen type, administration route, dose, and treatment duration...
April 8, 2024: Allergy
#10
Marie-Charlotte Brüggen, Stephan Traidl, Yasutaka Mitamura, Sarah Walsh, Lars E French, Nicholas Gulati, Elizabeth Phillips, Emanual Maverakis, Saskia Ingen-Housz-Oro
No abstract text is available yet for this article.
April 8, 2024: Allergy
#11
JOURNAL ARTICLE
Sven Becker, Sachin Deshmukh, Ferdinandus De Looze, Veronica Francardo, Jessie Lee, Anthony McGirr, Zachary Nathan, Christopher Rook, Thomas Meyer
RATIONALE: Saline nasal sprays are frequently used in the management of seasonal allergic rhinitis (SAR) for the cleansing and clearing of aeroallergens from the nasal cavity. Also using a drug-free approach, AM-301 nasal spray is forming a thin film barrier on the nasal mucosa to prevent contact with allergens, trap them, and facilitate their discharge. A clinical trial compared the efficacy, safety, and tolerability of AM-301 and saline spray in SAR. METHODS: A total of 100 patients were randomized 1:1 to self-administer AM-301 or saline 3 × daily for 2 weeks...
April 6, 2024: Allergy
#12
LETTER
Hwan Jin Lee, Min Ji Kim, Jong Seung Kim, Yong Chul Lee, Jae Seok Jeong
No abstract text is available yet for this article.
April 5, 2024: Allergy
#13
JOURNAL ARTICLE
Franziska Hartung, Pascal Haimerl, Sonja Schindela, Veronika Mussack, Benedikt Kirchner, Fiona D R Henkel, Ulrike Bernhardt, Ulrich M Zissler, Rachel Santarella-Mellwig, Michael Pfaffl, Carsten B Schmidt-Weber, Adam M Chaker, Julia Esser-von Bieren
BACKGROUND: Extracellular vesicles (EVs) have been implicated in the pathogenesis of asthma, however, how EVs contribute to immune dysfunction and type 2 airway inflammation remains incompletely understood. We aimed to elucidate roles of airway EVs and their miRNA cargo in the pathogenesis of NSAID-exacerbated respiratory disease (N-ERD), a severe type 2 inflammatory condition. METHODS: EVs were isolated from induced sputum or supernatants of cultured nasal polyp or turbinate tissues of N-ERD patients or healthy controls by size-exclusion chromatography and characterized by particle tracking, electron microscopy and miRNA sequencing...
April 4, 2024: Allergy
#14
LETTER
Patterns of allergen recognition in Ligustrum polysensitized patients: An immunoproteomics approach.
Raúl Porras-Gutiérrez-de-Velasco, Blessy Maruthukunnel-Mani, Juan Carlos Vizuet-de-Rueda, Josaphat Miguel Montero-Vargas, Luis M Teran
No abstract text is available yet for this article.
April 4, 2024: Allergy
#15
JOURNAL ARTICLE
Ioana Agache, Isabella Annesi-Maesano, Lorenzo Cecchi, Benedetta Biagioni, Kian Fan Chung, Bernard Clot, Gennaro D'Amato, Athanasios Damialis, Stefano Del Giacco, Javier Dominguez-Ortega, Carmen Galàn, Stefanie Gilles, Stephen Holgate, Mohamed Jeebhay, Stelios Kazadzis, Kari Nadeau, Nikolaos Papadopoulos, Santiago Quirce, Joaquin Sastre, Fiona Tummon, Claudia Traidl-Hoffmann, Jolanta Walusiak-Skorupa, Marek Jutel, Cezmi A Akdis
The EAACI Guidelines on the impact of short-term exposure to outdoor pollutants on asthma-related outcomes provide recommendations for prevention, patient care and mitigation in a framework supporting rational decisions for healthcare professionals and patients to individualize and improve asthma management and for policymakers and regulators as an evidence-informed reference to help setting legally binding standards and goals for outdoor air quality at international, national and local levels. The Guideline was developed using the GRADE approach and evaluated outdoor pollutants referenced in the current Air Quality Guideline of the World Health Organization as single or mixed pollutants and outdoor pesticides...
April 2, 2024: Allergy
#16
JOURNAL ARTICLE
Emma Guttman-Yassky, Kenji Kabashima, Delphine Staumont-Salle, Walter K Nahm, Sylvia Pauser, Joel Correa Da Rosa, Britta Cathrina Martel, Daniel Elenius Madsen, Mads Røpke, Petra Arlert, Louise Steffensen, Andrew Blauvelt, Kristian Reich
BACKGROUND: Tralokinumab is a monoclonal antibody that specifically neutralizes interleukin (IL)-13, a key driver of skin inflammation and barrier abnormalities in atopic dermatitis (AD). This study evaluated early and 2-year impacts of IL-13 neutralization on skin and serum biomarkers following tralokinumab treatment in adults with moderate-to-severe AD. METHODS: Skin biopsies and blood samples were evaluated from a subset of patients enrolled in the Phase 3 ECZTRA 1 (NCT03131648) and the long-term extension ECZTEND (NCT03587805) trials...
April 2, 2024: Allergy
#17
Allen P Kaplan, Marta Ferrer
No abstract text is available yet for this article.
April 1, 2024: Allergy
#18
LETTER
Andrzej Bozek, Magdalena Krupka-Olek, Aleksandra Kawczyk Krupka
No abstract text is available yet for this article.
March 30, 2024: Allergy
#19
REVIEW
Jan Brozek, Ewa Borowiack, Ewelina Sadowska, Artur Nowak, Bernardo Sousa-Pinto, Rafael José Vieira, Antonio Bognanni, Juan Jose Yepes Nuñez, Yuan Zhang, Torsten Zuberbier, Jean Bousquet, Holger J Schünemann
BACKGROUND: Allergic rhinitis (AR) impacts patients' physical and emotional well-being. Assessing patients' values and preferences (V&P) related to AR is an essential part of patient-centered care and of the guideline development process. We aimed to systematically summarize the information about patients' V&P on AR and its symptoms and impact on daily life. METHODS: We conducted systematic review in a MEDLINE, Embase, PsychInfo, and CINAHL databases. We included studies which quantitatively assessed patients' V&P for specific outcomes in AR by assessing utilities, applying discrete choice approaches, or rating and ranking outcomes...
March 29, 2024: Allergy
#20
EDITORIAL
Luo Zhang, Cezmi A Akdis
No abstract text is available yet for this article.
March 27, 2024: Allergy
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
